Piramal Pharma Receives 'Leader' ESG Rating of 67.1 from Niche99
Piramal Pharma Ltd 路 Others (Uncategorized) 路 19 Sept 2026, 1:09 am
Piramal Pharma Receives 'Leader' ESG Rating of 67.1 from Niche99 Piramal Pharma Limited announced that Niche Ninety Nine Capability and Certifications (OPC) Private Limited (Niche99) has assigned the company an Environment, Social, and Governance (ESG) rating of 67.1, placing it in the 'Leader' band. The assessment was communicated via BSE on 17th Sep'26. The company clarified that it did not engage Niche99 for the rating, which was independently prepared using publicly available information.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- Please find enclosed intimation of the exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited. 路 18 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund 路 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 路 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. 路 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. 路 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 路 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 路 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
